Comparative Pharmacology
Head-to-head clinical analysis: ORUDIS versus RIMADYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORUDIS versus RIMADYL.
ORUDIS vs RIMADYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Selective cyclooxygenase-2 (COX-2) inhibitor, reducing prostaglandin synthesis involved in inflammation, pain, and fever.
Oral: 50 mg three times daily or 75 mg twice daily; maximum 300 mg/day. Topical: Apply 2-4 g of gel or cream to affected area four times daily. Intramuscular: 50-100 mg every 4-6 hours; maximum 200 mg/day.
50-100 mg orally twice daily, or 100-200 mg rectally once daily (suppository).
None Documented
None Documented
Terminal half-life: ~1.5-2 hours for immediate-release; 30-50% increase in elderly due to reduced clearance. Clinical context: short half-life requires frequent dosing for sustained analgesia; no accumulation with q6-8h dosing.
Terminal elimination half-life: 12–18 hours in dogs at recommended doses. Clinical context: Supports twice-daily dosing; longer half-life in some breeds may require dose adjustment.
Renal: ~60% as metabolites (glucuronides of ketoprofen and hydroxylated metabolites); fecal: ~30% (biliary excretion); unchanged drug: <1% in urine.
Primarily hepatic metabolism (oxidation, conjugation) with ~70% of metabolites excreted in urine and ~30% in feces via biliary elimination. Less than 5% excreted unchanged.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)